These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 23928062)

  • 1. B cell receptor signaling in chronic lymphocytic leukemia.
    Burger JA; Chiorazzi N
    Trends Immunol; 2013 Dec; 34(12):592-601. PubMed ID: 23928062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
    ten Hacken E; Burger JA
    Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
    Patton JT; Woyach JA
    Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic Lymphocytic Leukemia: Disease Biology.
    Koehrer S; Burger JA
    Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Ten Hacken E; Gounari M; Ghia P; Burger JA
    Leukemia; 2019 Feb; 33(2):287-298. PubMed ID: 30555163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
    Koehrer S; Burger JA
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
    ten Hacken E; Burger JA
    Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V; Mraz M
    Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells.
    Efremov DG; Gobessi S; Longo PG
    Autoimmun Rev; 2007 Dec; 7(2):102-8. PubMed ID: 18035318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
    Wiestner A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
    Montresor A; Toffali L; Rigo A; Ferrarini I; Vinante F; Laudanna C
    Oncotarget; 2018 Oct; 9(80):35123-35140. PubMed ID: 30416684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
    Burger JA
    Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.